The work, summarized in a Research Briefing by Nature Biotechnology, combines two ingredients that have rarely been brought together so systematically: high-throughput experimentation and Bayesian optimization. Bayesian optimization is a machine learning strategy designed for exactly the kind of problem the vaccine engineers faced, in which each experiment is costly, the search space of possible formulations is vast, and the relationship between the ingredients and the outcome is complex and poorly understood. Rather than testing every conceivable combination of stabilizing sugars, buffering agents, drying protocols and nanoparticle compositions, the algorithm builds a probabilistic model of the formulation landscape from the data gathered so far, then selects the next experiment where the expected gain in information or performance is highest.

This data-efficient approach matters because traditional formulation development is notoriously slow. A medicinal chemist or vaccine formulator might adjust one variable at a time, run stability assays that take days or weeks to complete, and iterate over months or years. By contrast, AGENT closes the loop: robotic high-throughput platforms prepare large batches of candidate formulations, automated assays measure their stability and bioactivity, and the Bayesian optimizer digests each round of results to propose an improved set of conditions for the next. The framework effectively takes the human out of the loop for the routine decision-making, reserving human judgment for defining the objectives and validating the final candidates.

The target of the optimization was a solid-state mRNA vaccine, meaning that the mRNA-lipid nanoparticles are dried into a stable matrix rather than suspended in liquid. Drying is a well-known route to thermal stability for biological drugs, as the absence of water dramatically slows the hydrolysis and other degradation reactions that destroy RNA. But the drying process itself is stressful: ice crystals, osmotic shocks and the removal of the hydration shell can shear nanoparticles, aggregate them, or otherwise wreck the delicate structure that allows them to fuse with cell membranes and release their payload. The art lies in choosing protective excipients, often sugars such as trehalose or sucrose, and processing conditions that let the nanoparticles pass through drying and reconstitution unscathed.

The results reported by Tian and colleagues are striking on several fronts. The optimized solid-state formulations retained full bioactivity after two months of storage at 37 degrees Celsius, a condition far beyond anything current liquid mRNA vaccines can tolerate. In immunization studies, these stored vaccines elicited immune responses that were non-inferior to those generated by fresh, never-stressed formulations, which is the critical regulatory benchmark: a thermostable vaccine is only useful if it works as well as the product it replaces. Stability at room temperature and above would allow vaccines to be shipped and stored without the elaborate cold chain of ultra-low-temperature freezers, dry ice and temperature loggers that dominates current distribution.

The team went beyond vials and syringes. The thermostable mRNA formulations were incorporated into microneedle patches, small arrays of dissolving needles that painlessly deliver vaccine into the skin. Microneedle delivery has been pursued for years as a needle-free, potentially self-administered vaccination platform, and earlier work from some of the same community demonstrated a microneedle vaccine printer for thermostable COVID-19 mRNA vaccines. The new study extends that vision by showing that the AI-optimized, cold-chain-free formulations could be delivered via microneedle patches in rodents and nonhuman primates, providing proof of concept in animals that are far closer to humans than cell cultures or mice alone.

The combination of thermostability and patch delivery points toward a fundamentally different model of vaccine distribution. A vaccine that survives months at 37 degrees Celsius and can be applied as a patch requires no freezer, no trained phlebotomist, no reconstitution step and minimal medical waste. In resource-constrained settings, where the cited literature on vaccine accessibility emphasizes that storage and distribution bottlenecks cost lives, such a product could reach communities that conventional campaigns struggle to serve. It would also simplify pandemic preparedness, since stockpiles would not depend on a continuous chain of refrigeration stretching from factory to clinic.

From a technical standpoint, the study is a showcase of how modern machine learning changes the economics of formulation science. Bayesian optimization is particularly suited to problems with expensive evaluations because it balances exploration and exploitation: it probes regions of the design space where the model is uncertain, while also refining candidates that already look promising. The framework’s data efficiency means that the number of physical experiments needed to reach an optimized formulation can be a fraction of what a grid search or one-variable-at-a-time approach would demand. Each experiment feeds back into a surrogate model, typically a Gaussian process or similar probabilistic regressor, which quantifies not just the predicted performance of untested formulations but the confidence in those predictions.

The subjects attached to the paper, spanning biomaterials for vaccines, biomedical engineering, DNA and RNA science, and nanoparticles, reflect the interdisciplinary nature of the achievement. The mRNA-lipid nanoparticle platform sits at the intersection of nucleic acid chemistry, colloid science, polymer physics and immunology, and no single discipline could have solved the stability problem alone. What AGENT contributes is a unifying optimization layer that treats the entire formulation-and-processing pipeline as a single search problem, allowing trade-offs to be navigated automatically. A choice of excipient that improves drying stability but slows release, for example, can be weighed against alternatives in a principled way rather than by intuition.

Caveats remain, as they always do at this stage of translation. The immunogenicity data are from rodents and nonhuman primates, and human clinical trials will be needed to confirm that the optimized solid-state vaccines match the performance of approved liquid products in people. Two months of stability at 37 degrees Celsius is a dramatic improvement, but regulators will want to see longer-term data across a range of temperatures and humidities, along with manufacturing scale-up studies. Nonetheless, the demonstration that an AI-driven, data-efficient framework can compress years of formulation development into a rapid, systematic campaign is itself a significant result. If the approach generalizes to other mRNA drugs and vaccine targets, the cold chain that has long constrained global health delivery may finally begin to loosen.

Subject of Research: AI-guided Bayesian optimization for the development of thermostable, solid-state mRNA-lipid nanoparticle vaccines

Article Title: AI-guided optimization for thermostable mRNA vaccines

Article References: AI-guided optimization for thermostable mRNA vaccines. (2026). Nature Biotechnology. https://doi.org/10.1038/s41587-026-03330-x

Image Credits: AI Generated

DOI: 10.1038/s41587-026-03330-x

Keywords: mRNA vaccines, artificial intelligence, Bayesian optimization, lipid nanoparticles, thermostability, cold chain, microneedle patches, high-throughput experimentation, vaccine formulation, global health, biotechnology, immunization

Writing in Nature Biotechnology, Jinbi Tian, Khanh T. M. Tran, and colleagues describe AGENT, short for Algorithm-Guided Experimental design for lipid Nanoparticle Thermostabilization. The platform couples high-throughput experimentation with Bayesian optimization, a machine-learning strategy that is specifically built for situations where every experiment is costly and data are scarce. Rather than screening thousands of candidate formulations blindly, AGENT extracts the maximum amount of information from each small batch of results, using Gaussian process models to predict how untested excipient combinations will behave and to decide which experiments to run next.

The formulation problem the team tackled is genuinely multidimensional. To convert liquid mRNA–lipid nanoparticles into a solid-state, water-free product, the researchers used vacuum drying and then had to identify a cocktail of excipients—sugars, buffers, and other stabilizing agents—that would preserve the nanoparticles’ structure and the mRNA’s bioactivity through drying and subsequent storage. The search space of possible excipient types, ratios, and concentrations is enormous, and the relationships between composition and stability are nonlinear and poorly understood. Traditional one-factor-at-a-time approaches, the authors note, have been constrained by narrow formulation scope and low-throughput screening, which is precisely why prior stabilization efforts have progressed slowly.

Bayesian optimization changes the economics of that search. The algorithm maintains a probabilistic model of the entire design space and, at each iteration, balances exploration of uncertain regions against exploitation of promising ones, typically using an expected-improvement acquisition function to select the next experiment. Implemented within the AutODEx platform developed at MIT’s Computer Science and Artificial Intelligence Laboratory, AGENT completed its optimization in just six iterative rounds within a single month—a pace that would be unattainable with conventional design-of-experiments workflows, which often require many more cycles and far more material to converge on an optimum.

The results are striking. The team worked with two clinically relevant lipid nanoparticle systems, one based on SM-102, the ionizable lipid in Moderna’s vaccine, and the other on ALC-0315, used by Pfizer-BioNTech. After optimization, both were converted into solid-state formulations that retained 100 percent of their bioactivity after more than two months of storage at 37 degrees Celsius—roughly human body temperature. For a class of products that normally degrades within hours or days at room temperature, that level of thermal tolerance represents a qualitative leap, and it was achieved without altering the core lipid compositions already validated in clinics.

Stability on the shelf means little if the vaccine no longer works in the body, so the researchers subjected their thermostable formulations to a demanding battery of animal tests. In rodents, solid-state SARS-CoV-2 vaccine formulations delivered by standard injection induced antigen-specific immune responses that were non-inferior to those elicited by freshly prepared liquid vaccines given intramuscularly. The team then pushed the concept further, incorporating the stabilized nanoparticles into microneedle patches—tiny arrays of dissolving needles that painlessly deliver vaccine into the skin and could, in principle, be mailed to patients or administered by minimally trained personnel.

The microneedle experiments extended into non-human primates, a critical translational step. Patch delivery of the thermostable solid-state vaccine in cynomolgus monkeys again produced antigen-specific immune responses comparable to conventional intramuscular injection of freshly prepared vaccine. Because microneedle patches eliminate the need for needles, syringes, and highly trained injectors, and because the solid-state formulation removes the need for refrigeration, the combination addresses two of the most persistent bottlenecks in global immunization campaigns simultaneously.

The significance of the work extends beyond any single vaccine. The mRNA–LNP platform is now being pursued for cancer immunotherapies, gene editing, and treatments for rare genetic diseases, and all of these applications inherit the same storage fragility. Solid-state, water-free formulations open the door to integrating mRNA payloads into emerging delivery modalities, from microneedle patches to other advanced systems, that would be incompatible with a liquid product requiring ultra-cold handling. The authors also point out that the cold chain carries substantial economic and environmental costs, with estimates suggesting that vaccine distribution inefficiencies contribute significantly to global inequity in immunization coverage.

Methodologically, the study adds to a growing body of evidence that Bayesian optimization can compress discovery timelines in materials science and pharmaceutical development, where experiments are expensive and the parameter space is combinatorially large. Similar approaches have accelerated the identification of 3D printing materials and complex heterostructures, and the MIT team has made both its datasets, deposited in a public Zenodo repository, and its source code openly available, lowering the barrier for other laboratories to adopt the workflow. The optimization framework treats excipient selection as a multi-objective problem, allowing researchers to specify what matters—potency retention, storage stability, manufacturability—and let the algorithm navigate trade-offs automatically.

Caveats remain before thermostable mRNA vaccines reach clinics. The reported storage data cover months rather than years, and regulatory agencies will require extensive documentation of long-term stability, manufacturing consistency, and safety under Good Manufacturing Practice conditions. Human clinical trials of solid-state formulations and microneedle delivery lie ahead. Yet the demonstration that AI-guided experimentation can find stabilizing excipient compositions in six iterations and one month suggests that the development bottleneck may no longer be the search itself. If the approach generalizes across payloads and lipid systems, the freezer—and the costly, fragile supply chain it demands—could finally become optional for mRNA medicine.

Subject of Research: AI-guided optimization of thermostable solid-state mRNA–lipid nanoparticle vaccine formulations

Article Title: Accelerated discovery of thermostable mRNA–lipid nanoparticle vaccines using data-efficient AI

Article References: Tian, J., Tran, K. T. M., Pogostin, B. H., Sheridan, O., Mursalova, S., Lee, A. H., Liu, S., Hamkins, J., Antov, D., Power, A. L., Dash, Z. S., Yun, D., Konaković Luković, M., Langer, R. S., & Jaklenec, A. (2026). Accelerated discovery of thermostable mRNA–lipid nanoparticle vaccines using data-efficient AI. Nature Biotechnology. https://doi.org/10.1038/s41587-026-03331-w

Image Credits: AI Generated

DOI: 10.1038/s41587-026-03331-w

Keywords: mRNA vaccines, lipid nanoparticles, Bayesian optimization, thermostability, cold chain, microneedle patches, vacuum drying, excipients, SARS-CoV-2, drug delivery, machine learning, Nature Biotechnology